COSMOS Pharmaceutical Corporation (3349.T)

Better than 9843.T's revenue of 928.95B.

Better than 9843.T's revenue growth rate of 3.70%.

Better than 9843.T's depreciation of 33.74B.

Better than 9843.T's receivables of 71.87B.

Better than 9843.T's receivables as percentage of revenue of 7.74%.

Better than 9843.T's inventories of 118.21B.

Better than 9843.T's inventories as percentage of revenue of 12.73%.

Better than 9843.T's weighted average cost of capital (wacc) of 6.70%.

Better than 9843.T's cost of equity of 7.20%.

Better than 9843.T's beta of 0.68.

Better than 9843.T's diluted shares outstanding of 113.01M.

Better than 9843.T's total debt of 203.02B.

Better than 9843.T's debt weighting of 11.14%.

Better than 9843.T's equity weighting of 88.86%.

Better than 9843.T's unlevered free cash flow of -22.86B.

Better than 9843.T's long-term growth rate of 1.00%.

Better than 9843.T's net debt of 41.10B.

Better than 9843.T's equity value of 343.19B.

Better than 9843.T's equity value per share of 3036.74.